Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

BACKGROUND: The third-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated EGFR-mutated non-small cell lung cancer (NSCLC) who acquire the T790M resistance mutation. However, no standard treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Yuxin, Hao, Xuezhi, Yang, Ke, Ma, Di, Wang, Shouzheng, Xu, Ziyi, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602986/
https://www.ncbi.nlm.nih.gov/pubmed/31124059
http://dx.doi.org/10.1007/s11523-019-00644-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602986/
https://www.ncbi.nlm.nih.gov/pubmed/31124059
http://dx.doi.org/10.1007/s11523-019-00644-6

Ejemplares similares